Journal Article

Combination Antibiotic Therapy for Infective Endocarditis

Ellie J. C. Goldstein, Thuan Le and Arnold S. Bayer

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 5, pages 615-621
Published in print March 2003 | ISSN: 1058-4838
Published online March 2003 | e-ISSN: 1537-6591 | DOI:
Combination Antibiotic Therapy for Infective Endocarditis

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Despite the availability of new and potent antibiotics, modern echocardiography, and advanced surgical techniques, infective endocarditis (IE) is still associated with high morbidity and mortality rates. Use of synergistic antibiotic combinations is an appealing way to optimize therapy for IE. This review focuses on evidence-based recommendations for combination antimicrobial therapy for IE due to the most common etiologic pathogens. Few proven synergistic approaches for the treatment of IE have been globally demonstrated via in vitro models, experimental IE models, and human clinical trials, except for IE due to enterococci. Novel approaches, such as short-course aminoglycoside therapy and double–β-lactam combination therapy, appear to be promising for treatment of enterococcal IE. Short-course combination therapy involving agents with activity against the cell wall (CWAs) and aminoglycosides is highly effective for IE caused by viridans group streptococci. Although synergistic combination therapy with CWAs-aminoglycosides remains widely used by clinicians for Staphylococcus aureus IE, few definitive human data exist that demonstrate the clinical benefit of such an approach.

Journal Article.  5078 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.